226 related articles for article (PubMed ID: 23970479)
1. mRNA splicing variants: exploiting modularity to outwit cancer therapy.
Dehm SM
Cancer Res; 2013 Sep; 73(17):5309-14. PubMed ID: 23970479
[TBL] [Abstract][Full Text] [Related]
2. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
4. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
5. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
6. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.
Wang Y; Bao Y; Zhang S; Wang Z
Sci China Life Sci; 2020 Apr; 63(4):469-484. PubMed ID: 32086672
[TBL] [Abstract][Full Text] [Related]
7. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
[TBL] [Abstract][Full Text] [Related]
8. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
9. Splicing in oncogenesis and tumor suppression.
Kaida D; Schneider-Poetsch T; Yoshida M
Cancer Sci; 2012 Sep; 103(9):1611-6. PubMed ID: 22691055
[TBL] [Abstract][Full Text] [Related]
10. Targeting mRNA processing as an anticancer strategy.
Desterro J; Bak-Gordon P; Carmo-Fonseca M
Nat Rev Drug Discov; 2020 Feb; 19(2):112-129. PubMed ID: 31554928
[TBL] [Abstract][Full Text] [Related]
11. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
[TBL] [Abstract][Full Text] [Related]
12. Impact of alternative splicing on mechanisms of resistance to anticancer drugs.
Reviejo M; Soto M; Lozano E; Asensio M; Martínez-Augustin O; Sánchez de Medina F; Marin JJG
Biochem Pharmacol; 2021 Nov; 193():114810. PubMed ID: 34673012
[TBL] [Abstract][Full Text] [Related]
13. Entropy measures quantify global splicing disorders in cancer.
Ritchie W; Granjeaud S; Puthier D; Gautheret D
PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
[TBL] [Abstract][Full Text] [Related]
14. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
[TBL] [Abstract][Full Text] [Related]
15. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
16. Regulation of chemoresistance via alternative messenger RNA splicing.
Eblen ST
Biochem Pharmacol; 2012 Apr; 83(8):1063-72. PubMed ID: 22248731
[TBL] [Abstract][Full Text] [Related]
17. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
18. Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma.
Anobile DP; Montenovo G; Pecoraro C; Franczak M; Ait Iddouch W; Peters GJ; Riganti C; Giovannetti E
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):305-322. PubMed ID: 35533249
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease-related gene variants influence pre-mRNA splicing processes.
Gaweda-Walerych K; Mohagheghi F; Zekanowski C; Buratti E
Neurobiol Aging; 2016 Nov; 47():127-138. PubMed ID: 27574110
[TBL] [Abstract][Full Text] [Related]
20. [Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance].
Vegran F; Boidot R; Oudin C; Riedinger JM; Lizard-Nacol S
Bull Cancer; 2005 Mar; 92(3):219-26. PubMed ID: 15820916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
